As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2025 in the “Cancer Drug Development” Section, which are listed below:

1. “Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index”
by Jue Gong, Wenqiu Zhang and Joseph P. Balthasar
Cancers 2025, 17(6), 1032; https://doi.org/10.3390/cancers17061032
Available online: https://www.mdpi.com/2072-6694/17/6/1032

2. “New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment”
by Cristina Amaral, Cristina F. Almeida, Maria João Valente, Carla L. Varela, Saul C. Costa, Fernanda M. F. Roleira, Elisiário Tavares-da-Silva, Anne Marie Vinggaard, Natércia Teixeira and Georgina Correia-da-Silva
Cancers 2025, 17(2), 165; https://doi.org/10.3390/cancers17020165
Available online: https://www.mdpi.com/2072-6694/17/2/165

3. “Advances in the Repurposing and Blood–Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors”
by Julian S. Rechberger, Stephanie A. Toll, Subhasree Biswas, Hyo Bin You, William D. Chow, Nicholas Kendall, Pournima Navalkele and Soumen Khatua
Cancers 2025, 17(3), 439; https://doi.org/10.3390/cancers17030439
Available online: https://www.mdpi.com/2072-6694/17/3/439

4. “The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies”
by Carmen Besliu, Alina Daniela Tanase, Ionela Rotaru, Jose Espinoza, Laura Vidal, Martine Poelman, Manel Juan, Carlos Fernández de Larrea and Kamal S. Saini
Cancers 2025, 17(3), 525; https://doi.org/10.3390/cancers17030525
Available online: https://www.mdpi.com/2072-6694/17/3/525

5. “Morpholine-Substituted Tetrahydroquinoline Derivatives as Potential mTOR Inhibitors: Synthesis, Computational Insights, and Cellular Analysis”
by Rajdeep Dey, Suman Shaw, Ruchi Yadav, Bhumika D. Patel, Hardik G. Bhatt, Gopal Natesan, Abhishek B. Jha and Udit Chaube
Cancers 2025, 17(5), 759; https://doi.org/10.3390/cancers17050759
Available online: https://www.mdpi.com/2072-6694/17/5/759

6. “Novel Biological Strategies for Melanoma Therapy: A Focus on lncRNAs and Their Targeting”
by Francesca Maria Orlandella, Rosaria Arcone, Neila Luciano, Giuliana Salvatore and Maria Letizia Motti
Cancers 2025, 17(8), 1273; https://doi.org/10.3390/cancers17081273
Available online: https://www.mdpi.com/2072-6694/17/8/1273

7. “Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study”
by Farshid Dayyani, Heide A. Stirnadel-Farrant, Jenny Hu, Yian Lin, Nehemiah Kebede, Stephen J. Valerio and Daniel H. Ahn
Cancers 2025, 17(2), 305; https://doi.org/10.3390/cancers17020305
Available online: https://www.mdpi.com/2072-6694/17/2/305

8. “Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database”
by Razvan Constantin Vonica, Claudiu Morgovan, Anca Butuca, Manuela Pumnea, Remus Calin Cipaian, Adina Frum, Carmen Maximiliana Dobrea, Andreea Loredana Vonica-Tincu, Aliteia-Maria Pacnejer, Florina Batar et al.
Cancers 2025, 17(4), 663; https://doi.org/10.3390/cancers17040663
Available online: https://www.mdpi.com/2072-6694/17/4/663

9. “ECM Stiffness-Induced Redox Signaling Enhances Stearoyl Gemcitabine Efficacy in Pancreatic Cancer”
by Shuqing Zhao, Edward Agyare, Xueyou Zhu, Jose Trevino, Sherise Rogers, Enrique Velazquez-Villarreal, Jason Brant, Payam Eliahoo, Jonathan Barajas, Ba Xuan Hoang et al.
Cancers 2025, 17(5), 870; https://doi.org/10.3390/cancers17050870
Available online: https://www.mdpi.com/2072-6694/17/5/870

10. “Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia”
by Clifford M. Csizmar, Mark R. Litzow and Antoine N. Saliba
Cancers 2025, 17(5), 779; https://doi.org/10.3390/cancers17050779
Available online: https://www.mdpi.com/2072-6694/17/5/779

11. “Navigating Stomatologic Complications Secondary to Antineoplastic Agents—A Comprehensive Review”
by Ion Alexandru Popovici, Lidia Anca Kajanto, Laura Roxana Popovici, Iolanda Georgiana Augustin and Laurentia Nicoleta Gales
Cancers 2025, 17(7), 1061; https://doi.org/10.3390/cancers17071061
Available online: https://www.mdpi.com/2072-6694/17/7/1061

12. “Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy”
by Changjun Yu, Faqing Huang, Leslie Wang, Mengmeng Liu, Warren A. Chow, Xiang Ling, Fengzhi Li, Galen Cook-Wiens, Linrong Li and Xiaojiang Cui
Cancers 2025, 17(5), 881; https://doi.org/10.3390/cancers17050881
Available online: https://www.mdpi.com/2072-6694/17/5/881

13. “A Cross-Sectional Survey of Oral Adverse Events and Oral Management Needs in Outpatients Receiving Cancer Drug Therapy”
by Yuki Sakai, Kouji Katsura, Masaaki Kotake and Akira Toyama
Cancers 2025, 17(4), 641; https://doi.org/10.3390/cancers17040641
Available online: https://www.mdpi.com/2072-6694/17/4/641

14. “An Overview of Cellular and Molecular Determinants Regulating Chemoresistance in Pleural Mesothelioma”
by Lourdes Cortes-Dericks and Domenico Galetta
Cancers 2025, 17(6), 979; https://doi.org/10.3390/cancers17060979
Available online: https://www.mdpi.com/2072-6694/17/6/979

15. “Role of Rac1 in p53-Related Proliferation and Drug Sensitivity in Multiple Myeloma”
by Ikuko Matsumura, Tsukasa Oda, Tetsuhiro Kasamatsu, Yuki Murakami, Rei Ishihara, Ayane Ohmori, Akira Matsumoto, Nanami Gotoh, Nobuhiko Kobayashi, Yuri Miyazawa et al.
Cancers 2025, 17(3), 461; https://doi.org/10.3390/cancers17030461
Available online: https://www.mdpi.com/2072-6694/17/3/461

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.